Literature DB >> 31951906

Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Kirsten E Smith1, Martha D Tillson2, Michele Staton3, Erin M Winston4.   

Abstract

BACKGROUND: Illicit, medically unsupervised use of buprenorphine (i.e., "diverted use") among vulnerable and underserved populations, such as corrections-involved adults, remains underexplored.
METHODS: Survey data (2016-2017) collected as part of a clinical assessment of incarcerated adults entering corrections-based substance use treatment in Kentucky were analyzed. For years examined, 12,915 completed the survey. Removing cases for participants who did not reside in Kentucky for >6 months during the one-year pre-incarceration period (n = 908) resulted in a final sample size of 12,007.
RESULTS: Over a quarter of the sample reported past-year diverted buprenorphine use prior to incarceration and 21.8 % reported use during the 30-days prior to incarceration, using 6.5 months and 14.3 days on average, respectively. A greater proportion of participants who reported diverted buprenorphine use had previously been engaged with some substance use treatment (77.0 %) and reported greater perceived need for treatment (79.4 %) compared to those who did not report use. Use was more likely among participants who were younger, white, male, and who reported rural or Appalachian residence. Diverted buprenorphine users also evidenced extensive polydrug use and presented with greater substance use disorder severity. Non-medical prescription opioid, heroin, and diverted methadone use were associated with increased odds of diverted buprenorphine use while kratom was not. Diverted methadone use was associated with a 252.9 % increased likelihood of diverted buprenorphine use.
CONCLUSIONS: Diverted buprenorphine use among participants in this sample was associated with concerning high-risk behaviors and may indicate barriers to accessing opioid agonist therapies for corrections-involved Kentucky residents, particularly those in rural Appalachia.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Diversion; Heroin; Opioid agonist therapies; Polydrug use

Mesh:

Substances:

Year:  2020        PMID: 31951906      PMCID: PMC7418075          DOI: 10.1016/j.drugalcdep.2020.107837

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  127 in total

1.  Attitudes and practices regarding the use of methadone in US state and federal prisons.

Authors:  Josiah D Rich; Amy E Boutwell; David C Shield; R Garrett Key; Michelle McKenzie; Jennifer G Clarke; Peter D Friedmann
Journal:  J Urban Health       Date:  2005-05-25       Impact factor: 3.671

2.  Rural risk environments for hepatitis c among young adults in appalachian kentucky.

Authors:  David H Cloud; Umedjon Ibragimov; Nadya Prood; April M Young; Hannah L F Cooper
Journal:  Int J Drug Policy       Date:  2019-05-18

3.  Medications For Addiction Treatment: Changing Language to Improve Care.

Authors:  Sarah E Wakeman
Journal:  J Addict Med       Date:  2017 Jan/Feb       Impact factor: 3.702

4.  Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Authors:  Hannu Alho; David Sinclair; Erkki Vuori; Antti Holopainen
Journal:  Drug Alcohol Depend       Date:  2006-10-19       Impact factor: 4.492

5.  Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.

Authors:  Michelle R Lofwall; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2012-06-15       Impact factor: 4.492

6.  The opioid and related drug epidemics in rural Appalachia: A systematic review of populations affected, risk factors, and infectious diseases.

Authors:  Christine A Schalkoff; Kathryn E Lancaster; Bradley N Gaynes; Vivian Wang; Brian W Pence; William C Miller; Vivian F Go
Journal:  Subst Abus       Date:  2019-08-12       Impact factor: 3.716

7.  Trends and Patterns of Opioid Analgesic Prescribing: Regional and Rural-Urban Variations in Kentucky From 2012 to 2015.

Authors:  Huong Luu; Svetla Slavova; Patricia R Freeman; Michelle Lofwall; Steven Browning; Heather Bush
Journal:  J Rural Health       Date:  2018-04-17       Impact factor: 4.333

8.  Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices.

Authors:  Kai MacDonald; Kristy Lamb; Michael L Thomas; Wendy Khentigan
Journal:  Subst Use Misuse       Date:  2016-01-15       Impact factor: 2.164

9.  Factors associated with high-frequency illicit methadone use among rural Appalachian drug users.

Authors:  Martin T Hall; Carl G Leukefeld; Jennifer R Havens
Journal:  Am J Drug Alcohol Abuse       Date:  2013-07       Impact factor: 3.829

10.  Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis.

Authors:  Hannah K Knudsen; Lewei Allison Lin; Michelle R Lofwall
Journal:  Subst Abus       Date:  2019-07-11       Impact factor: 3.984

View more
  2 in total

1.  Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.

Authors:  Elizabeth A Evans; Ekaterina Pivovarova; Thomas J Stopka; Claudia Santelices; Warren J Ferguson; Peter D Friedmann
Journal:  J Subst Abuse Treat       Date:  2022-02-23

2.  Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.

Authors:  Anna Cheng; Ryan Badolato; Andrew Segoshi; Ryan McDonald; Mia Malone; Kumar Vasudevan; Beita Badiei; Allison Sugarman; Ross Macdonald; Jasdeep Mangat; Jonathan Giftos; Joshua D Lee; Babak Tofighi
Journal:  Addict Sci Clin Pract       Date:  2022-01-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.